UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 309

Sortiert nach

Antiviral activity of tenofovir alafenamide (TAF) against HIV‐1 clinical isolates harboring K65R

Journal of medical virology, 2023-04, Vol.95 (4), p.e28723-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Rapid HIV‐1 genotyping assay for the detection of capsid mutations

Journal of medical virology, 2023-12, Vol.95 (12), p.e29292-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

The Journal of infectious diseases, 2022-11, Vol.226 (11), p.1985-1991

2022

Link zum Volltext

Verfügbarkeit prüfen

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

The New England journal of medicine, 2022-05, Vol.386 (19), p.1793-1803

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

Antimicrobial agents and chemotherapy, 2015-10, Vol.59 (10), p.5917-5924

2015

Link zum Volltext

Verfügbarkeit prüfen

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

PloS one, 2017-02, Vol.12 (2), p.e0172206-e0172206

2017

Link zum Volltext

Verfügbarkeit prüfen

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

The Journal of infectious diseases, 2017-03, Vol.215 (6), p.920-927

2017

Link zum Volltext

Verfügbarkeit prüfen

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

Antiviral research, 2016-08, Vol.132, p.50-58

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2654-2663

2013

Link zum Volltext

Verfügbarkeit prüfen

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

Journal of medical virology, 2019-12, Vol.91 (12), p.2188-2194

2019

Link zum Volltext

Verfügbarkeit prüfen

Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE

Journal of medical virology, 2019-05, Vol.91 (5), p.890-893

2019

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2345-2353

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

The Lancet infectious diseases, 2012, Vol.12 (1), p.27-35

2012

Link zum Volltext

Verfügbarkeit prüfen

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

The Journal of infectious diseases, 2023-12

2023

Link zum Volltext

Verfügbarkeit prüfen

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

AIDS (London), 2011-01, Vol.25 (3), p.325-333

2011

Link zum Volltext

Verfügbarkeit prüfen

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

AIDS research and therapy, 2014-12, Vol.11 (1), p.39-39

2014

Link zum Volltext

Verfügbarkeit prüfen

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Antiviral research, 2012-02, Vol.93 (2), p.288-296

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

Antimicrobial Agents and Chemotherapy, 2002-11, Vol.46 (11), p.3437-3446

2002

Link zum Volltext

Verfügbarkeit prüfen

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934

Journal of acquired immune deficiency syndromes (1999), 2009-10, Vol.52 (2), p.209

2009

Link zum Volltext

Verfügbarkeit prüfen

Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors

PloS one, 2013-06, Vol.8 (6), p.e65631

2013

Link zum Volltext

Verfügbarkeit prüfen

Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral-Experienced Patients

The Journal of infectious diseases, 2004-03, Vol.189 (5), p.837-846

2004

Link zum Volltext

Verfügbarkeit prüfen

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

The Internet journal of infectious diseases, 2013-06, Vol.207 (suppl_2), p.S70-S77

2013

Link zum Volltext

Verfügbarkeit prüfen

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

Antimicrobial agents and chemotherapy, 2021-02, Vol.65 (3)

2021

Link zum Volltext

Verfügbarkeit prüfen

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

AIDS (London), 2005-11, Vol.19 (16), p.1751-1760

2005

Link zum Volltext

Verfügbarkeit prüfen

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

AIDS (London), 2002-06, Vol.16 (9), p.1227-1235

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 309

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(283)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Antiviral activity of tenofovir alafenamide (TAF) against HIV‐1 clinical isolates harboring K65R

Rapid HIV‐1 genotyping assay for the detection of capsid mutations

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934

Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors

Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral-Experienced Patients

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

Suchergebnisse filtern